Homozygous Familial Hypercholesterolemia Clinical Trials

70 clinical trials for Homozygous Familial Hypercholesterolemia across international registries, including 14 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias — RECRUITING · PHASE1
• Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects with Homozygous Familial Hypercholesterolemia (YOSEMITE) — RECRUITING · PHASE3
• A Dose-exploration Study of EDP167 in HoFH — RECRUITING · PHASE2
• Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) — RECRUITING
• Two part (double-blind inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2]) randomized multicenter study to evaluate safety, tolerability and efficacy of inclisiran in children (2 to less than 12 years) with homozygous familial hypercholesterolemia and elevated LDL-cholesterol (ORION-19) — RECRUITING · PHASE3
• The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository — RECRUITING
• The ORIGIN-FH Study — RECRUITING · NA
• HoFH, the International Clinical Collaborators Registry — RECRUITING
• NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia — RECRUITING · PHASE1
• SAFETY AND EFFECTIVENESS OF EVINACUMAB FOR THE TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN A REAL LIFE SETTING IN CANADA — RECRUITING
• PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ARO-ANG3 IN SUBJECTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) — RECRUITING · PHASE2
• A PHASE 2 OPEN-LABEL STUDY TO ASSESS THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY AND TOLERABILITY OF ISIS 703802 (AKCEA-ANGPTL3LRX) ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) — RECRUITING · PHASE2
• AN OPEN-LABEL LONG-TERM EXTENSION TO THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, CROSS-OVER STUDY OF ROSUVASTATIN IN CHILDREN AND ADOLESCENTS (AGED 6 TO <18 YEARS) WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA — RECRUITING
• AN OPEN-LABEL, SINGLE-ARM, PROOF-OF-CONCEPT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE AND MULTIPLE DOSES OF REGN1500 IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA — RECRUITING
• An Open-label Study to Characterize Safety and Tolerability of Repatha in Homozygous Familial Hypercholesterolemia in India — OTHER · PHASE4
• A 12-week, open-label , all subjects will first receive 2 weeks of placebo drug and then active medication in a dose escalating manner: each patient will first receive 50 mg, after evaluation the option exists to increase the dose to to 100 mg and after another evaluation to 200 mg active study drug, phase 2 study to evaluate the effects of MBX-8025 in patients with Homozygous Familial Hypercholesterolemia (HoFH) — COMPLETED · PHASE2
• Effect of CER-001 on blockage of arteries (plaque) in subjects with homozygous familial hypercholesterolemia — COMPLETED · PHASE2
• A study to evaluate the effect of ALN-PCSSC treatment in patients with Homozygous Familial Hypercholesterolemia — COMPLETED · PHASE2
• A Phase III, Long Term, Open Label, Follow on Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor ‘lomitapide’ (AEGR-733) in Patients with Homozygous Familial Hypercholesterolemia — COMPLETED · PHASE3
• A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients with Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy — COMPLETED · PHASE3
• A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) — ACTIVE_NOT_RECRUITING · PHASE3
• Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Subjects (age 12 to <18 years) with Homozygous Familial Hypercholesterolemia (SPRUCE) — NOT_YET_RECRUITING · PHASE3
• Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH) — TERMINATED · PHASE2
• Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia — NOT_YET_RECRUITING · PHASE3
• LOWER: Lomitapide Observational Worldwide Evaluation Registry — COMPLETED
• A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients — ACTIVE_NOT_RECRUITING · PHASE3
• Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia — ACTIVE_NOT_RECRUITING
• A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia — COMPLETED · PHASE3
• Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia — COMPLETED · PHASE2
• Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia — NOT_YET_RECRUITING · PHASE2
• Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia — COMPLETED · PHASE3
• Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia — COMPLETED · PHASE3
• Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia — COMPLETED · PHASE3
• Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C — COMPLETED · PHASE3
• A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia — COMPLETED · PHASE2
• A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH) — TERMINATED · PHASE1
• Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH — COMPLETED · PHASE3
• A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501 — OTHER
• A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH — COMPLETED · PHASE2
• A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH) — COMPLETED · PHASE3
• Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED) — COMPLETED
• Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) — COMPLETED · PHASE3
• Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia — COMPLETED · NA
• Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia — COMPLETED · PHASE3
• Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients — COMPLETED
• TWO PART (DOUBLE-BLIND INCLISIRAN VERSUS PLACEBO [YEAR 1] FOLLOWED BY OPEN-LABEL INCLISIRAN YEAR 2]) RANDOMIZED MULTICENTER STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF INCLISIRAN IN ADOLESCENTS (12 TO LESS THAN 18 YEARS) WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AND ELEVATED LDL-CHOLESTEROL (ORION-13) — COMPLETED
• A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH) — COMPLETED · PHASE2
• A THREE-PART, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATETHE EFFICACY,SAFETY, AND PHARMACOKINETICS OFEVINACUMAB IN PEDIATRIC PATIENTS WITH HOMOZYGOUSFAMILIAL HYPERCHOLESTEROLEMIA. — NOT_YET_RECRUITING
• Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH) — COMPLETED · PHASE2
• HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia — OTHER · NA

Refine this search